High dose hypofractionated proton beam therapy is a safe and feasible treatment for central lung cancer

Radiology and Oncology

Takashi Ono¹  Tomonori Yabuuchi²  Tatsuya Nakamura³  Hitoshi Wada³  Yasuhiro Kikuchi³  Motohisa Suzuki³  Yusuke Azami³  Kanako Kimura³  Katsumi Hirose³  Kenji Nemoto⁴ 

[1] Corresponding authorDepartment of Radiation Oncology, Southern Tohoku Proton Therapy Center, 7-172, Yatsuyamada, Koriyama, Fukushima, Japan;Department of Radiation Oncology, Ninohe Hospital, 38 - 2, Okawarage, Aza, Horino, Ninohe, Iwate, JapanOther articles by this author:;Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, 7-172, Yatsuyamada, Koriyama, Fukushima, JapanOther articles by this author:;Department of Radiation Oncology, Yamagata University Faculty of Medicine, 2-2-2, Iida-Nishi, Yamagata, JapanOther articles by this author:

关键词: central;    lung cancer;    hypofractionated;    proton beam therapy;   

DOI  :  10.1515/raon-2017-0023

学科分类：肿瘤学

来源: Onkoloski Institut Ljubljana / Institute of Oncology Ljubljana

【 摘 要 】

BackgroundThere have been few reports about high total dose hypofractionated proton beam therapy for central lung cancer. The aim of this study was to examine retrospectively the safety and efficacy of high total dose hypofractionated proton beam therapy for central lung cancer.

【 授权许可】

Unknown